Moreover, mutating the C79A+C88A palmitoylation sites of TM4SF1 in 4T1 cancer cells decreased metastatic burden of mice compared to control cells expressing wildtype TM4SF1 regardless of whether the cells were injected intravenously or in the mammary fat pad (Figure 5d, 5e, Extended Data Figure 5e, 5f). This evidence concerns the gene TM4SF1 and cancer.